Cancer / Immunology
KaliVir’s VET3-TGI Regimens Show 71% Response Rate in Advanced Skin Cancers in Early Trial
Preliminary data from intratumoral VET3-TGI presented in oral session at SITC 2026; abstract recognized among SITC’s top 150 abstracts Responses o...
November 10, 2026 | News
OncoC4 Reports 33% Response Rate for Cesalatamig in Lung Cancer Resistant to PD-(L)1 Therapy
33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refrac...
November 09, 2026 | News
VS Pharmtech Advances Radiotherapy Enhancer VS-101 to Phase 2 in the US
Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anti...
November 09, 2026 | News
NCCN and Vietnam Partners Expand Cancer Guideline Collaboration to Include Lymphomas and Thyroid Cancer
NCCN and Viet Nam National Cancer Hospital sign agreement to enhance ongoing guideline adaptation efforts with the inclusion of additional hematologic...
November 06, 2026 | News
Akeso’s Ivonescimab Plus Chemotherapy Granted Priority Review in China for First-Line Biliary Tract Cancer
Akeso, Inc. announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer...
November 06, 2026 | News
Pierre Fabre Launches BRAFTOVI–MEKTOVI Combination for BRAF-Mutant Lung Cancer in Singapore
New targeted treatment option now available in for adult patients with BRAFV600E mutant advanced non-small cell lung cancer (NSCLC) Launch follows Europ...
November 04, 2026 | News
Lynk Pharmaceuticals Expands Simcere Partnership to Commercialise Zemprocitinib for Atopic Dermatitis in Greater China
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Gro...
November 03, 2026 | News
Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements ac...
November 02, 2026 | News
Innovent Seeks China Approval for Sintilimab and Nolgileucel Combination in Advanced Melanoma
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
October 28, 2026 | News
EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...
October 28, 2026 | News
Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
October 26, 2026 | News
Lunit and Summit Therapeutics Join Forces to Decode Tumour Biology with AI-Powered Pathology
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Bi...
October 26, 2026 | News
Akeso and Summit Advance Ivonescimab into Seventh Global Registrational Trial Targeting Biliary Tract Cancer
Akeso, Inc. announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration wit...
October 23, 2026 | News
Therakos Secures EU MDR Approval for First-of-Its-Kind Therapy to Manage Cancer Immunotherapy Toxicities
Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced t...
October 23, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
